Pimozide and Ziprasidone: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Combining antipsychotics can increase central, extrapyramidal and cardiac adverse effects. Pimozide combined with an established systemic QT-prolonging medicine presents a serious arrhythmia risk.
Clinical significance and safety
Pimozide and Ziprasidone: Combining antipsychotics can increase central, extrapyramidal and cardiac adverse effects. Pimozide combined with an established systemic QT-prolonging medicine presents a serious arrhythmia risk. This combination is contraindicated under the cited pimozide product information for established QT-prolonging partners. It needs prompt prescriber or pharmacist review, not self-directed dose changes. Heart disease, a slow pulse and low potassium or magnesium can increase concern. A clinician determines whether ECG or electrolyte checks are needed. Fainting or new irregular palpitations require urgent assessment. Concurrent antipsychotic treatment or a planned switch requires specialist review of movement symptoms, alertness, balance and cardiac risk. A class precaution is not evidence that all such combinations are absolutely contraindicated.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.